Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07303712 · ClinicalTrials.gov registry record
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
A clinical trial of Hepatocellular Carcinoma (HCC), sponsored by Palo Alto Veterans Institute for Research.
- Recruiting
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT07303712 is a study of Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 12 participants, below the 350-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07303712, a study of Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by Palo Alto Veterans Institute for Research.
- RECRUITING
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Conditions Studied
Study Locations (1)
California
- VA Palo Alto Health Care System - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2026-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07303712
The ClinicalTrials.gov registry entry for NCT07303712 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 350-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (97% lower). The listed sponsor is Palo Alto Veterans Institute for Research, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 0 interventions.
NCT07303712 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07303712 about?
NCT07303712 is a clinical study titled "Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90". The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinom...
What is the current status of trial NCT07303712?
This trial is currently recruiting. The enrollment target is 12 participants. The study started on 2024-08-01. Estimated completion is 2026-12-01.
What conditions does trial NCT07303712 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).
Who is sponsoring clinical trial NCT07303712?
This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07303712 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma (HCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
RECRUITING
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
The Dragon PLC Trial (DRAGON-PLC)
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.